
Why strong science isn’t enough to raise capital
There’s a moment most biotech founders know well. The science is solid. The team is credible. The data is strong. And yet, somewhere between the pitch deck and the term sheet, something breaks down. In 2020 we had an oncology company client with a strong scientific platform, five first-in-class programs,






